Product Description
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Brain Stem Cancer|HIV Infections|Sarcoma, Kaposi
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCI-2012-02924 | P2 |
Terminated |
HIV Infections|Sarcoma, Kaposi |
2005-11-01 |
2020-10-26 |
||
| CDR0000066830 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2002-04-01 |
2019-03-21 |
Treatments |
|
| CDR0000067379 | P2 |
Completed |
Brain Stem Cancer |
None |
2019-03-21 |
Treatments |